Director Alan Sebulsky purchases 17,500 shares across 3 transactions for $473,528.54, increasing stake by 140% to 30,000 shares.
Alan Sebulsky, a Director at Parabilis Medicines, executed 3 separate purchases totaling 17,500 shares for $473,528.54 between June 12–15, 2026, at prices ranging from $26.00 to $27.67 (blended average $27.06). The aggregate purchase increased his holdings from 12,500 shares to 30,000 shares, representing a 140% increase in position size. The purchases occurred within days of the company's recent IPO listing (5 trading days old as of the filing date), and the current market price of $26.59 sits just below the blended transaction price of $27.06. The concentrated and substantial nature of this multi-transaction purchase—nearly tripling director holdings over a compressed timeframe—is noteworthy for a newly public company where director positioning during the initial post-listing period may signal conviction or reflect capital allocation strategy at a critical juncture in the company's public market history.